| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BioHarvest Sciences Inc. Common Stock
$1.8
-0.1 (-5.26%)
Market Cap
29.57 M
EPS
-0.61
P/E Ratio
-
Value Trade
244.38 K
-2.17 %
Week
-20.35 %
1 Month
-43.57 %
3 Month
-57.35 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
134.79 K
52 Week Range
1.80 - 12.80
% held by Insiders
16.12 %
% held by Institutions
9.71 %
Enterprise Value
91.32 M
Total Shares
16.43 M
Short %
0.5 %
Float Shares
14.92 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioHarvest Sciences Inc. Common Stock
122Total events
6Upcoming
15Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 2
TBD
T2Ipo
Subscribe to view catalyst details
TBD
T3Manufacturing Milestone
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BHST
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BHST Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BHST
Sep 3, 2026▼ -5.3%today
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
BioHarvest Sciences Inc. has announced its intention to dual-list its shares on the Tel Aviv Stock Exchange (TASE) alongside its existing Nasdaq listing. The shares are expected to begin trading on September 8, 2026. CEO Dr. Zaki Rakib highlighted the growth potential and connection with the Israeli investment community as key motivations for this move.
Read more →-BHST
Jun 18, 2026BioHarvest Sciences to Present at the 2026 BIO International Convention
BioHarvest Sciences Inc. will present its Botanical Synthesis platform at the BIO International Convention in San Diego from June 22-25, 2026. The presentation aims to demonstrate the technology's potential in producing pharmaceutical-grade plant-derived compounds. The event offers a platform for engaging with pharmaceutical organizations and exploring strategic collaborations.
Read more →-BHST
Jun 18, 2026DATED JUNE 18, 2026 News Release dated
BioHarvest Sciences Inc. announced its participation in the 2026 BIO International Convention to showcase its proprietary Botanical Synthesis platform. Scheduled for June 24, the presentation aims to attract strategic partnerships to exploit the technology's potential in drug discovery and pharmaceutical applications. The company highlights its expansive capabilities and recent initiatives, focusing on the long-term value for its shareholders. However, challenges such as uncertain future contracts and market acceptance remain as significant considerations.
Read more →-BHST
May 18, 2026TATE & LYLE EXPANDS COLLABORATION WITH BIOHARVEST SCIENCES TO ACCELERATE NEXT-GENERATION SWEETENER INNOVATION
BioHarvest Sciences has expanded its collaboration with Tate & Lyle to develop multiple plant-based sweeteners. This initiative aims to provide diverse sweetening solutions tailored to various food and beverage categories, enhancing consumer choice and supporting health goals. The partnership leverages BioHarvest's Botanical Synthesis technology to create sustainable, non-GMO ingredients.
Read more →-BHST
May 14, 2026BioHarvest Sciences Reports First Quarter 2026 Financial Results
BioHarvest Sciences reported its first-quarter financial results for 2026, achieving an 8% increase in revenue year-over-year, totaling $8.5 million. Significant milestones were reached in the CDMO division, with a remarkable 135% growth in CDMO revenue. However, the company also reported an increased net loss of $2.6 million compared to $2.3 million from the previous year. The VINIA brand continues to thrive, boasting 90,000 active users and contributing significantly to the company's revenue.
Read more →-BHST
May 14, 2026Unaudited Interim Condensed Consolidated Financial Statements
BioHarvest Sciences Inc. released its unaudited interim consolidated financial statements for the three months ended March 31, 2026. The financial results show an increase in gross profit to $5,037 compared to $4,595 in the same quarter last year, although the net loss has risen to $2,641 from $2,338. Current liabilities have also increased, and the total assets declined from $47,665 to $45,558. The company continues developing its Botanical Synthesis technology, which aims to enhance production while minimizing negative environmental impacts.
Read more →-BHST
May 13, 2026BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
BioHarvest Sciences has successfully completed Stage 1 of its development for a saffron composition aimed at nutraceutical and culinary applications. This achievement marks a significant milestone in the company's efforts to innovate within these markets. The new composition is expected to provide enhanced benefits and broaden the scope of saffron use.
Read more →-BHST
May 13, 2026MATERIAL CHANGE REPORT DATED MAY 13, 2026 News Release dated
BioHarvest Sciences has announced the successful completion of Stage 1 in its saffron development program, establishing a stable saffron cell bank. This advancement triggers a move to Stage 2 of a multi-stage development agreement valued at $1.125 million, focusing on the production of saffron-derived ingredients for nutraceutical and culinary applications. BioHarvest holds a 25% ownership stake in the saffron composition being developed. The company believes its Botanical Synthesis platform can sustainably address the global saffron market's supply constraints.
Read more →-BHST
May 12, 2026BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using its Proprietary Botanical Synthesis Platform
BioHarvest Sciences has signed a $1.2 million Stage 2 contract with an unnamed UAE investment firm to develop a rare fragrance using its proprietary Botanical Synthesis technology. Following a successful Stage 1, the company aims to produce enough material for commercial trials within 6-9 months, setting the stage for entry into the $23 billion premium fragrance market by late 2027. With continued investment in manufacturing capacities, BioHarvest is positioned to establish long-term royalty-driven revenue streams.
Read more →-BHST
May 11, 2026▼ -7.1%on this newsshared move
MATERIAL CHANGE REPORT DATED MAY 11, 2026 Material Change Report dated
BioHarvest Sciences Inc. has announced a leadership transition, appointing Dr. Zaki Rakib as the new CEO, replacing Ilan Sobel who will now serve on the Board of Directors. This shift aims to streamline operations in both the direct-to-consumer and CDMO sectors. Dr. Rakib's extensive experience and prior leadership role are expected to further propel the company's growth. Under Sobel, the company grew from a pre-revenue phase to generating approximately $35 million in revenue in 2025.
Read more →-BHST
Apr 30, 2026DATED APRIL 30, 2026 News Release dated
BioHarvest Sciences Inc. announced it will report its first quarter 2026 financial results on May 14, 2026. A conference call and webcast will occur at 8:00 a.m. Eastern Time, aimed at discussing results and providing business updates. The company specializes in its Botanical Synthesis technology, which allows it to develop plant-based compounds without cultivating the actual plants. Attendees are encouraged to register for the webcast ahead of time, and a recorded replay will be available afterward.
Read more →-BHST
Apr 29, 2026BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate “Two-Lens” Growth Strategy
BioHarvest Sciences has announced a leadership transition with Dr. Zaki Rakib becoming the new CEO, consolidating R&D, Manufacturing, and Operations under a unified structure. Ilan Sobel, the former CEO, will now focus on the company's direct-to-consumer business as a Board member. This strategic move aims to enhance the company's two-lens growth strategy and strengthen its market position.
Read more →-BHST
Apr 29, 2026DATED APRIL 29, 2026 News Release dated
BioHarvest Sciences has announced a significant leadership transition, appointing Dr. Zaki Rakib as the new CEO while transitioning Ilan Sobel to the Board of Directors. This move aims to strengthen the execution of the company's 'two-lens' strategy, which focuses on direct-to-consumer (D2C) growth and enhancing capabilities within its Contract Development and Manufacturing Organization (CDMO). Dr. Rakib's experience and leadership within the company are seen as pivotal for future growth, particularly in consolidating the company's operations. Sobel's prior success as CEO and continued board involvement is viewed as beneficial for expanding BioHarvest’s market presence.
Read more →-BHST
Mar 31, 2026BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform
BioHarvest Sciences has achieved a significant milestone by successfully completing Stage 1 of a development program for a rare fragrance-producing plant. This marks the first-ever stable cell culture creation for the endangered plant, positioning the company to tap into the lucrative fragrance market. The proprietary Botanical Synthesis platform played a crucial role in this achievement, allowing for the sustainable production of valuable fragrance compounds. BioHarvest aims to advance to Stage 2, with expectations for pre-commercial testing within 6 to 9 months.
Read more →-BHST
Mar 31, 2026BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
BioHarvest Sciences reported strong financial results for FY2025, with revenues reaching $34.5 million, a 37% increase from the previous year. The company successfully launched VINIA Blood Flow Hydration and secured significant financing. Despite a projected adjusted EBITDA loss for 2026, BioHarvest maintains a solid cash position of $23 million.
Read more →-BHST
Mar 26, 2026BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States
BioHarvest Sciences has announced that its product VINIA has become the leading resveratrol polyphenol brand in the United States. This achievement highlights the brand's strong market presence and consumer preference. The company attributes this success to effective marketing strategies and the quality of its product.
Read more →-BHST
Mar 26, 2026DATED MARCH 26, 2026 News Release dated
BioHarvest Sciences Inc. announced that its VINIA brand has become the top Resveratrol Polyphenol Nutraceutical Brand in the U.S., reflecting its strong market presence and the success of the Botanical Synthesis platform. The product has shown clinically proven ability to enhance arterial dilation and blood flow, contributing to improved health outcomes. With over $30 million in U.S. revenue during 2025 and a growing subscription base, VINIA's performance highlights the effectiveness of BioHarvest's innovative technology. Overall, VINIA's success underscores the increasing consumer recognition and adoption of its health benefits.
Read more →-BHST
Mar 17, 2026BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
BioHarvest Sciences Inc. will report its fourth quarter and full year 2025 financial results on March 31, 2026. The company will host a conference call and webcast at 4:30 p.m. EDT to discuss the results and provide updates on its operations. The earnings call will be accessible live and will also be available for replay on their website.
Read more →-BHST
Mar 17, 2026DATED MARCH 17, 2026 News Release dated
BioHarvest Sciences Inc. has announced that it will report its fourth quarter and full year financial results for 2025 on March 31, 2026. The announcement includes details for a conference call and webcast to discuss the results and the company's business operations. These results are anticipated following the company's continued development in its Botanical Synthesis platform, indicating its focus on both transparency and innovation in the market.
Read more →-BHST
Mar 13, 2026DATED MARCH 13, 2026 News Release dated
BioHarvest Sciences has announced the approval of long-term incentive awards for its employees, officers, and directors, designed to align the interests of the team with shareholders. The grants comprise 516,812 stock options and 264,121 restricted share units, which will vest quarterly over three years. This initiative aims to support the company's growth and innovation while maintaining cash management discipline. However, the company acknowledges potential risks associated with retaining key personnel and external uncertainties affecting its value.
Read more →-BHST
Mar 6, 2026MATERIAL CHANGE REPORT DATED MARCH 6, 2026 Material Change Report dated
BioHarvest Sciences Inc. reported a change in its board of directors, with David Tsur resigning and Prof. Hezi Levy appointed as his replacement. Prof. Levy brings extensive experience, having previously served as Director General of the Israeli Ministry of Health and led major health initiatives during the COVID-19 pandemic. His appointment is seen as a strategic move to bolster the company's leadership with robust healthcare expertise.
Read more →-BHST
Mar 5, 2026BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
BioHarvest Sciences has announced a transition in its board, appointing Prof. Hezi Levy as a new member. This strategic move is intended to strengthen the company's governance and direction. Prof. Levy's extensive experience is anticipated to contribute positively to the company's future growth.
Read more →-BHST
Mar 5, 2026BioHarvest Sciences Announces Board Transition and Appointment of Prof.
BioHarvest Sciences Inc. announced a leadership change with Mr. David Tsur stepping down from the Board of Directors after four years, effective immediately. Prof. Hezi Levy has been appointed to the Board, bringing decades of experience in healthcare leadership, notably during his tenure as Director General of the Israeli Ministry of Health. The Chairman expressed gratitude for Mr. Tsur's contributions and highlighted the significance of Prof. Levy's expertise in strengthening the company's governance and growth initiatives.
Read more →-BHST
Mar 3, 2026BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026
BioHarvest Sciences Inc. has been invited to the 38th Annual Roth Conference scheduled for March 22-24, 2026. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors during this high-profile event. The company is currently at an important inflection point following a successful financing round and aims to leverage its patented Botanical Synthesis technology for growth in its CDMO and consumer product sectors.
Read more →-BHST
Mar 3, 2026DATED MARCH 3, 2026 News Release dated
BioHarvest Sciences Inc. will participate in the 38th Annual Roth Conference from March 22-24, 2026, in Dana Point, California. CEO Ilan Sobel will meet with institutional investors to discuss the company's strategic direction and growth prospects, following a successful financing round in Q4 2025. With over 85,000 direct customers and a focus on plant-based compounds, BioHarvest aims to achieve significant milestones in 2026 through both its contract development and manufacturing operations and new wellness products.
Read more →-BHST
Jan 7, 2026BioHarvest Sciences Issues Year End Shareholder Letter
BioHarvest Sciences issued its year-end shareholder letter, highlighting a significant first year as a NASDAQ-listed company with an annualized revenue run rate above $36 million and gross margins exceeding 60%. The company plans aggressive growth in its D2C products, led by the VINIA brand, and reports positive consumer feedback on new offerings. Its CDMO Services division is onboarding major collaborative contracts and anticipates that future revenues will surpass its products division. With a strengthened balance sheet and expanded capabilities, BioHarvest is committed to accelerating growth and achieving adjusted EBITDA breakeven in the near future.
Read more →-BHST
Dec 18, 2025BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
BioHarvest Sciences has received a $1.6 million grant from the Israeli Innovation Authority to enhance its second-generation Botanical Synthesis platform. This funding will facilitate the integration of AI tools, increase bioreactor sizes, and expand manufacturing capabilities. The grant is non-dilutive, allowing the company to advance its R&D without impacting shareholder equity.
Read more →-BHST
Dec 18, 2025DATED DECEMBER 18, 2025 News Release dated
BioHarvest Sciences has been awarded a $1.6 million grant from the Israeli Innovation Authority to enhance its second-generation Botanical Synthesis platform. This funding is designed to advance the company's capabilities in artificial intelligence, manufacturing efficiency, and production scalability. The grant is non-dilutive and will further support BioHarvest's strategic plans without impacting shareholder equity. CEO Ilan Sobel highlighted the grant as a validation of the company's technology leadership.
Read more →-BHST
Dec 3, 2025BIOHARVEST SCIENCES ANNOUNCES LAUNCH OF VINIA BLOOD FLOW HYDRATION PRODUCT
BioHarvest Sciences has launched VINIA Blood Flow Hydration, the first hydration product utilizing VINIA's blood flow enhancing Piceid Resveratrol, in the U.S. This innovative solution aims to improve the delivery of fluids and electrolytes in a growing market worth $13 billion. The product has garnered positive responses from early adopters and is backed by a 90-day guarantee. BioHarvest aims to disrupt the hydration market by combining effective hydration with enhanced blood flow.
Read more →-BHST
Nov 16, 2025▼ -7.9%on this news
BioHarvest Sciences Reports Third Quarter 2025 Financial Results
BioHarvest Sciences reported a strong third quarter for 2025, achieving a 39% increase in revenue to $9.1 million, driven by growth in its VINIA product line and new CDMO partnerships. The company also successfully raised $19.9 million to strengthen its balance sheet. Despite a net loss of $2.5 million, management remains optimistic about future growth and product launches.
Read more →-BHST
Nov 13, 2025▼ -7.6%on this newsshared move
BIOHARVEST SCIENCES ANNOUNCES CLOSING OF $19.9 MILLION UPSIZED PUBLIC OFFERING OF COMMON STOCK AND EXERCISE OF UNDERWRITER’S OPTION TO PURCHASE ADDITIONAL SHARES
BioHarvest Sciences Inc. has successfully closed a $19.9 million public offering of common stock at $7.00 per share. The offering included additional shares purchased by underwriters and aims to fund manufacturing expansion, R&D, and other corporate purposes. CEO Ilan Sobel expressed optimism about the company's growth potential and welcomed new U.S. institutional investors.
Read more →-BHST
Nov 13, 2025▼ -7.6%on this newsshared move
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the T
BioHarvest Sciences Inc. released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The company reported a significant increase in total assets to $35,188, representing a growth from $25,001 in the previous year. Despite higher revenues of $25,442, the net loss for the period was reported at $8,931, which, while improved from previous year losses, indicates ongoing financial challenges. Overall, the results show a mixture of growth opportunities amid persistent operating losses and accrued liabilities.
Read more →-BHST
Nov 12, 2025▲ +14.8%on this newsshared move
DATED NOVEMBER 12, 2025 News Release dated
BioHarvest Sciences Inc. announced its attendance at the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, in New York, NY. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors during the event. The company is experiencing strong momentum in its consumer and contract development platform, driven by robust sales in its VINIA capsule business and new product offerings. BioHarvest’s recent successful equity offering indicates a focus on achieving profitability and sustainable growth.
Read more →-BHST
Nov 10, 2025DATED NOVEMBER 10, 2025 News Release dated
BioHarvest Sciences Inc. has successfully completed an underwritten public offering, raising $19.9 million by issuing 2,846,854 shares at a price of $7.00 each. The proceeds are aimed at funding various initiatives, including manufacturing expansion, research and development, and working capital. The offering was well-received and resulted in the inclusion of new U.S. institutional investors in the company's shareholder base. CEO Ilan Sobel expressed optimism about the capital raise and its potential to accelerate company growth.
Read more →-BHST
Nov 7, 2025▼ -8.9%on this newsshared move
MATERIAL CHANGE REPORT Material Change Report FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 . Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Street Vancouver, BC, V6C 2T6 (the "Company" or "BioH
BioHarvest Sciences Inc. has announced its intention to conduct an underwritten public offering of 2,485,000 shares of common stock at a price of $7.00 per share. The offering is expected to generate approximately $17.4 million in gross proceeds, which will be utilized for various corporate purposes, including research and development and debt refinancing. The company has granted underwriters a 30-day option to purchase additional shares, and the offering is anticipated to close around November 10, 2025, subject to customary conditions.
Read more →-BHST
Nov 6, 2025▼ -11.5%on this news· ran to -22% by day 3shared move
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time
BioHarvest Sciences Inc. will announce its third quarter financial results on November 13, 2025, after market close. An investor conference call will follow at 4:30 p.m. Eastern Time, providing a corporate update and a Q&A session. The company specializes in Botanical Synthesis technology, aiming to innovate in therapeutic solutions.
Read more →-BHST
Nov 4, 2025▼ -6.8%on this news· ran to -23% by day 3shared move
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m.
BioHarvest Sciences Inc. has announced it will hold a third quarter earnings call on November 13, 2025, at 4:30 p.m. Eastern Time. The call will discuss the financial results for the quarter ending September 30, 2025, and also provide a corporate update. Participants will have the opportunity to engage in a question-and-answer session. This call demonstrates the company's commitment to financial transparency and investor communication.
Read more →-BHST
Oct 31, 2025▼ -8.3%on this newsshared move
MATERIAL CHANGE REPORT DATED OCTOBER 31, 2025 Material Change Report dated
BioHarvest Sciences Inc. has announced a strategic CDMO agreement with Saffron Tech Ltd. to develop saffron-derived botanical compounds using its patented Botanical Synthesis platform. This collaboration aims to provide a sustainable production alternative to traditional saffron cultivation methods, which are hindered by climate change and various regional instabilities. The partnership plans to manufacture large-scale products for BioHarvest's e-commerce platform, focusing on the nutraceutical benefits of saffron. Notably, Saffron Tech holds 75% ownership of the developed compositions under this agreement.
Read more →-BHST
Oct 30, 2025BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical Synthesis
BioHarvest Sciences has announced a strategic partnership with Saffron Tech to develop saffron-derived botanical compounds using its patented Botanical Synthesis technology. This collaboration aims to enhance the production of saffron, a valuable spice, by eliminating the need for traditional cultivation methods. The partnership is expected to accelerate the path to market for saffron-based nutraceutical products, addressing supply chain challenges and environmental concerns.
Read more →-BHST
Oct 30, 2025DATED OCTOBER 30, 2025 News Release dated
BioHarvest Sciences Inc. announced a strategic CDMO partnership with Saffron Tech to enhance saffron compound production through its Botanical Synthesis platform. This collaboration aims to address the challenges associated with traditional saffron cultivation, such as high costs and seasonal volatility. BioHarvest anticipates revenue growth and product launches in the forthcoming fourth quarter of 2025, despite preliminary EBITDA losses. Saffron Tech will retain a significant share of the generated IP and compositions under the agreement.
Read more →-BHST
Sep 22, 2025BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and additional $3.8 Million in Debt Reduction
BioHarvest Sciences Inc. has successfully raised $10.9 million through accelerated warrant exercises and debt conversions, significantly strengthening its balance sheet. The company also reduced its total debt by $3.8 million, enhancing its financial flexibility for future growth. CEO Ilan Sobel emphasized the importance of these transactions for the company's ongoing initiatives in both product development and contract manufacturing.
Read more →-BHST
Sep 22, 2025MATERIAL CHANGE REPORT DATED SEPTEMBER 23, 2025 Material Change Report dated September 23,, 2025 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Str
BioHarvest Sciences Inc. announced in a material change report that it successfully completed warrant exercises and debt conversions totaling $10.9 million and $3.8 million, respectively. These transactions, aimed at enhancing the company's financial stability, include raising funds through the exercising of warrants and converting convertible notes into shares. The company is using the proceeds for capital expenditures, refinancing remaining debt, and working capital. Following these changes, BioHarvest's total debt is approximately $6.6 million.
Read more →-BHST
Sep 22, 2025DATED SEPTEMBER 22, 2025 News Release dated
BioHarvest Sciences Inc. has successfully completed a series of transactions to strengthen its balance sheet, raising $10.9 million in gross proceeds and reducing total debt by $3.8 million. The transactions included raising cash through the exercise of warrants and the conversion of debt to equity, designed to provide financial flexibility for future growth. CEO Ilan Sobel highlighted this as a pivotal milestone, enhancing their capacity for capital expenditures and working capital. The company aims to accelerate its initiatives across its product and CDMO services divisions.
Read more →-BHST
Sep 10, 2025BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale
BioHarvest Sciences has achieved a significant milestone by producing plant-based exosomes at scale using its proprietary bioreactor technology. This advancement not only enhances the bioavailability of therapeutic compounds but also opens new revenue opportunities in the cosmetics and health industries. The company anticipates launching a differentiated skincare product within 18 to 24 months, capitalizing on the growing demand for plant-based exosomes.
Read more →-BHST
Sep 10, 2025DATED SEPTEMBER 10, 2025 News Release dated
BioHarvest Sciences Inc. announced a major advancement in its Botanical Synthesis technology by successfully producing plant-based exosomes at scale. This development allows the company to explore new revenue opportunities within cosmetic and health sectors. The exosomes enhance the delivery of viniferin, a sought-after compound in skincare applications, and position BioHarvest to enter a growing market expected to reach $2.2 billion by 2030. The CEO expressed optimism about launching a differentiated skincare application within the next 18 to 24 months, leveraging the advanced absorption features of these exosomes.
Read more →-BHST
Sep 9, 2025BIOHARVEST SCIENCES INC.
BioHarvest Sciences Inc. has announced the effectiveness of its shelf registration statement on Form F-3 with the SEC. This allows the company to offer and sell up to $100 million in common shares, warrants, and units as needed depending on market conditions and capital requirements. Importantly, the registration does not obligate the company to sell any specific amount, maintaining flexibility. The move is intended to enhance the company's liquidity and support future initiatives, although it introduces variability based on market dynamics.
Read more →-BHST
Sep 8, 2025▼ -5.9%on this newsshared move
MATERIAL CHANGE REPORT DATED SEPTEMBER 9 , 2025 Material Change Report dated September 9 , 2025 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Stre
BioHarvest Sciences Inc. has announced the filing and effectiveness of a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. This registration allows the company to offer and sell up to USD $100 million of its securities, which includes common shares and warrants, depending on market conditions and capital needs. The company emphasizes that this registration does not guarantee any specific amount will be sold and remains at its discretion based on the market environment.
Read more →-BHST
Sep 2, 2025BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET
BioHarvest Sciences Inc. will host a Virtual Investor Webinar on September 10, 2025, led by CEO Ilan Sobel. The webinar aims to provide updates on new initiatives, including the company's 'Big Bets' for the second half of 2025, and will feature a Q&A session for participants. This event highlights the company's commitment to shareholder engagement and growth.
Read more →-BHST
Sep 2, 2025DATED SEPTEMBER 2, 2025 News Release dated
BioHarvest Sciences Inc. will host a virtual investor webinar on September 10, 2025, led by CEO Ilan Sobel. The event will cover corporate updates, including new capability-building initiatives and the company's strategic goals for the second half of 2025. Participants will have the opportunity to engage in a question-and-answer session following the presentation. This webinar highlights BioHarvest's commitment to transparency and its focus on driving profitable growth in the nutraceutical and contract development sectors.
Read more →-BHST
Aug 14, 2025MATERIAL CHANGE REPORT DATED AUGUST 14, 2025 Material Change Report dated
BioHarvest Sciences Inc. has updated its insider trading policy, as announced by the board of directors. The new policy establishes a revised trading window that begins two trading days after the public release of quarterly or year-end results, lasting until 15 days before the due date for those results. This change aims to establish a more reasonable timeframe for trading activities related to the company's financial disclosures. Further details can be obtained through the company's investor relations contact.
Read more →-BHST
Aug 13, 2025BioHarvest Sciences Amended Insider Trading Policy
BioHarvest Sciences Inc. has announced an amended insider trading policy, aimed at establishing a more reasonable trading window for its shareholders. The new trading window will open after two full trading days following the public release of quarterly or year-end results and will close 15 days prior to the due date for these results. This change is expected to promote transparency and align trading practices more closely with publicly available information. BioHarvest continues to leverage its patented Botanical Synthesis technology for developing innovative plant-based solutions.
Read more →-BHST
Aug 11, 2025BioHarvest Sciences Reports Second Quarter 2025 Financial Results
BioHarvest Sciences reported a robust 41% revenue growth in Q2 2025, reaching $8.5 million, driven by strong sales of its core VINIA capsule and new product launches. The company also secured a new CDMO contract and announced plans for several growth initiatives, including a professional affiliate program and a new electrolyte drink. However, the net loss increased to $4.0 million, attributed to higher operating expenses and non-cash finance costs.
Read more →-BHST
Aug 11, 2025DATED AUGUST 11, 2025 News Release dated
BioHarvest Sciences Inc. reported a robust 41% increase in revenues for the second quarter of 2025, reaching $8.5 million, largely driven by their core capsule business and new product launches. The company also validated its botanical synthesis platform through the successful completion of a Stage 1 development contract with a pharmaceutical company. Despite revenue growth, a net loss of $4 million was reported, and management highlighted rising operating expenses. Looking ahead, BioHarvest plans to launch multiple initiatives to enhance growth and reach adjusted EBITDA breakeven by the end of 2025.
Read more →-BHST
Aug 5, 2025BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m.
BioHarvest Sciences Inc. has announced an upcoming earnings call scheduled for August 11, 2025, at 8:00 a.m. Eastern Time to discuss its financial results for the second quarter of 2025. The call will provide an overview of the company's performance and a corporate update, concluding with a question-and-answer session for participants. This event highlights BioHarvest's commitment to transparency and investor communication.
Read more →-BHST
Jul 23, 2025▲ +5.6%on this news
BioHarvest Sciences to Present at Canaccord Genuity 45th Annual Growth Conference on August 12-14, 2025
BioHarvest Sciences Inc. has announced its participation in the Canaccord Genuity 45th Annual Growth Conference scheduled for August 12-14, 2025, in Boston. CEO Ilan Sobel will present and meet with institutional investors, highlighting the company's growth momentum in its consumer and CDMO sectors. The event aims to showcase BioHarvest's advancements in botanical synthesis technology.
Read more →-BHST
Jul 23, 2025▲ +5.6%on this newsshared move
DATED JULY 23, 2025 News Release dated
BioHarvest Sciences Inc. has announced its upcoming presentation at the Canaccord Genuity 45th Annual Growth Conference scheduled for August 12-14, 2025, in Boston. CEO Ilan Sobel will engage in one-on-one meetings with institutional investors and deliver a corporate presentation outlining the company's growth plans. The firm highlights its patented Botanical Synthesis technology and its dual business verticals in nutraceutical products and contract development. This event is seen as an opportunity to solidify investor confidence and showcase ongoing momentum in its operations.
Read more →-BHST
Jul 4, 2025MATERIAL CHANGE REPORT DATED JULY 4, 2025 Material Change Report dated
BioHarvest Sciences Inc. announced the outcomes of its annual general meeting held on June 26, 2025. Shareholders approved all proposed motions, including the election of directors and the establishment of a new Equity Incentive Compensation Plan. The company's articles were also amended to implement a staggered board, intended to provide greater board continuity. Auditors for the company were appointed, further solidifying governance structures.
Read more →-BHST
Jul 3, 2025Rehovot, Israel - July 2, 2025 - BioHarvest Sciences Inc.
BioHarvest Sciences Inc. held its annual general and special meeting on June 26, 2025, where shareholders approved all proposed motions, including changes to the board structure. The new board will be divided into three classes with staggered terms, allowing for a more organized governance approach. Additionally, shareholders elected six directors and confirmed the appointment of Ziv Haft as the company's auditors. The meeting also validated the company's Equity Incentive Compensation Plan.
Read more →-BHST
Jun 10, 2025TO ALL APPLICABLE REGULATORS AND EXCHANGES
BioHarvest Sciences Inc. has announced details for its upcoming Annual General & Special Meeting of Security Holders. The meeting is scheduled to take place on June 26, 2025, in Vancouver, BC, with a record date for notice and voting set for May 20, 2025. The announcement includes specifics regarding the securities involved and the procedures for beneficial ownership determination.
Read more →-BHST
Jun 4, 2025BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
BioHarvest Sciences Inc. has launched VINIA® DailyChews 2X Formula, designed to enhance nitric oxide production and improve blood flow for athletes and active individuals. The product is Informed Sport-certified, ensuring safety and efficacy for users. Available for purchase online, it aims to meet the demands of a younger consumer base in the nutraceuticals market.
Read more →-BHST
Jun 4, 2025DATED JUNE 4, 2025 News Release dated
BioHarvest Sciences Inc. has launched VINIA DailyChews 2X Formula, a chewable product aimed at enhancing nitric oxide production and blood flow for athletes and active individuals. Certified by Informed Sport, this product ensures safety by being tested for banned substances, making it appealing to professional athletes and fitness enthusiasts. This launch not only enlarges BioHarvest's product line but also positions the company within the growing nutraceutical market. Additionally, the new ecommerce platform facilitates international sales, thereby broadening customer reach.
Read more →-BHST
May 21, 2025BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
BioHarvest Sciences Inc. has announced a new contract to develop a plant-based fragrance compound, leveraging its Botanical Synthesis technology and AI tools. This contract marks the company's entry into the fragrance market, which is valued in the billions. The project will proceed in stages, with the first focusing on cell bank development. Successful outcomes could lead to further production phases.
Read more →-BHST
May 21, 2025DATED MAY 21, 2025 News Release dated
BioHarvest Sciences Inc. has announced a new contract for its Botanical Synthesis CDMO Services to develop a plant-based fragrance compound. This venture marks the company's entry into the multi-billion-dollar fragrance market, leveraging AI technology to select the optimal plant species for production. The agreement includes milestone payments and emphasizes the need for further development stages to achieve commercial viability. While this contract represents growth potential, certain uncertainties regarding future contracts and market acceptance remain.
Read more →-BHST
May 16, 2025BioHarvest Sciences Reports First Quarter 2025 Financial Results
BioHarvest Sciences reported a significant 47% increase in revenues for Q1 2025, reaching $7.9 million, surpassing management expectations. The company also noted an expansion in gross margins and a growing subscriber base for its VINIA® product. However, it recorded a net loss of $2.3 million and an adjusted EBITDA loss of $1.4 million, highlighting ongoing operational challenges. Management anticipates further growth and breakeven adjusted EBITDA in the second half of 2025.
Read more →-BHST
May 15, 2025DATED MAY 15, 2025 News Release dated
BioHarvest Sciences Inc. reported financial results for the first quarter of 2025, highlighting a 47% increase in revenues to $7.9 million, surpassing management guidance. The company also noted a growing subscriber base for its VINIA product, exceeding 50,000. However, despite the revenue growth, BioHarvest reported a net loss of $2.3 million for the quarter, signaling ongoing financial challenges that the company aims to address with upcoming product launches and strategies in its CDMO division.
Read more →-BHST
May 12, 2025BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company
BioHarvest Sciences Inc. has successfully completed Stage 1 of its CDMO contract with a Nasdaq-listed pharmaceutical company, validating its Botanical Synthesis platform. The next phase will focus on scaling biomass and optimizing growing conditions for commercial production. This milestone enhances BioHarvest's position as a trusted partner in developing plant-based therapeutic solutions.
Read more →-BHST
May 12, 2025DATED MAY 12, 2025 News Release dated
BioHarvest Sciences Inc. announced the successful transition of its contract development and manufacturing organization (CDMO) project from Stage 1 to Stage 2. This achievement validates their Botanical Synthesis technology, which isolates and multiplies plant cells for pharmaceutical use. Stage 1 focused on sourcing plants for compound development, while Stage 2 will test biomass suitability and optimize growing conditions. The company's leadership expressed optimism about future opportunities and the validated capabilities of their in-house AI tools.
Read more →-BHST
May 1, 2025BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time
BioHarvest Sciences Inc. will announce its financial results for Q1 2025 on May 15, 2025, after market close. Following the release, management will host a conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Participants can join via dial-in or webcast.
Read more →-BHST
May 1, 2025DATED MAY 1, 2025 News Release dated
BioHarvest Sciences Inc. will announce its first quarter 2025 financial results on May 15, 2025, after market close. Following the release, management will host a conference call to discuss the results and provide a corporate update. The call is scheduled for 4:30 p.m. Eastern Time and will include a question-and-answer session for participants. The company's innovative Botanical Synthesis technology positions it within the nutraceutical market as it develops various health and wellness products.
Read more →-BHST
Apr 1, 2025BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results
BioHarvest Sciences reported strong financial results for Q4 and full year 2024, with revenues increasing 62% and 99% respectively. The company secured a partnership with Tate & Lyle to develop plant-based sweeteners, enhancing its market position. Despite a net loss, management anticipates reaching adjusted EBITDA breakeven by the second half of 2025, supported by operational efficiencies and a growing subscriber base for its VINIA® products.
Read more →-BHST
Apr 1, 2025CERTIFICATION OF ANNUAL FILINGS - CEO Certification of Annual Filings - CEO Form 52-109F1 Certification of Annual Filings Full Certificate I, Ilan Sobel, the Chief Executive Officer of BioHarvest Sciences Inc. , certify
Ilan Sobel, CEO of BioHarvest Sciences Inc., has certified the annual filings for the financial year ending December 31, 2024. He confirmed that the filings do not contain any misleading statements and that the financial statements accurately represent the company's financial status. Additionally, he stated that the company has established adequate internal controls for disclosure and reporting. The certification indicates a commitment to transparency and accuracy in financial reporting.
Read more →-BHST
Mar 31, 2025▼ -5.6%on this newsshared move
DATED MARCH 31, 2025 News Release dated
BioHarvest Sciences Inc. reported robust financial results for Q4 and full year 2024, with revenues increasing significantly alongside operational enhancements. The Company announced a key partnership with Tate & Lyle, aiming to develop innovative plant-based sweeteners, thereby expanding its market reach. Management forecasts positive trends with expectations of reaching EBITDA breakeven in the latter half of 2025, despite a net loss in the fourth quarter. Additionally, BioHarvest continues to grow its VINIA product lines, which have seen increased subscriber engagement and sales.
Read more →-BHST
Mar 17, 2025DATED MARCH 17, 2025 Press Release dated
BioHarvest Sciences Inc. will host an earnings call on March 31, 2025, to discuss its financial results for the fourth quarter and full year ended December 31, 2024. The call will provide corporate updates along with a Q&A session, showcasing the company's commitment to engaging with investors. This event reflects BioHarvest's ongoing operations and financial transparency as a leader in Botanical Synthesis technology.
Read more →-BHST
Mar 6, 2025BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025
BioHarvest Sciences Inc. has been invited to the 37th Annual Roth Conference, scheduled for March 16-18, 2025. CEO Ilan Sobel will hold one-on-one meetings with institutional investors during the event. The company aims to showcase its growth story following its Nasdaq listing and the launch of its CDMO Services Division, which has achieved significant sales milestones.
Read more →-BHST
Mar 6, 2025DATED MARCH 6, 2025 Press Release dated
BioHarvest Sciences Inc. has announced its participation in the 37th Annual Roth Conference from March 16-18, 2025. CEO Ilan Sobel will engage in one-on-one meetings with institutional investors to showcase the company's growth prospects. BioHarvest highlights significant achievements, including a $50 Million cumulative sales milestone for its product VINIA and the recent launch of its CDMO Services Division. The event presents an opportunity for the company to promote its innovative Botanical Synthesis technology.
Read more →-BHST
Mar 4, 2025▲ +5.4%on this newsshared move
BioHarvest In Vitro testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells
BioHarvest Sciences Inc. announced positive in vitro results for its Olive Cell compound, which significantly reduces fat accumulation in liver cells. This compound targets Non-Alcoholic Fatty Liver Disease (NAFLD), affecting 30-40% of U.S. adults. The company plans to launch the product as a nutraceutical in 2026, while exploring pharmaceutical partnerships for broader regulatory pathways.
Read more →-BHST
Mar 4, 2025▲ +5.4%on this newsshared move
DATED MARCH 4, 2025 Press Release dated
BioHarvest Sciences Inc. has reported promising results from in vitro tests of its proprietary Olive Cell compound, which reduces fat accumulation in liver cells. This aims to address Non-Alcoholic Fatty Liver Disease (NAFLD), impacting a significant portion of U.S. adults. The company plans to market the Olive Cell product as a nutraceutical in 2026 and explores partnerships for pharmaceutical applications. While the results are optimistic, challenges remain regarding regulatory approval and market acceptance.
Read more →-BHST
Feb 18, 2025▲ +6.1%on this news
BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD
BioHarvest Sciences Inc. announced that its flagship product, VINIA, has surpassed $50 million in sales, primarily in the U.S. market. The company attributes this success to its patented Botanical Synthesis technology, which produces plant-based compounds. VINIA has gained over 50,000 active users and boasts a high customer satisfaction rating. BioHarvest plans to quadruple production capacity with a new facility expected by late 2026.
Read more →-BHST
Feb 18, 2025▲ +6.1%on this newsshared move
DATED FEBRUARY 18, 2025 Press Release dated
BioHarvest Sciences Inc. has announced that its flagship product, VINIA, has surpassed $50 million in cumulative sales within less than four years of its launch in the U.S. The supplement, derived from a patented Botanical Synthesis technology, boasts over 50,000 active users and a high customer satisfaction rating. The company is also planning to quadruple production capacity with a new facility by late 2026. However, there are inherent risks associated with the expansion and future product development.
Read more →-BHST
Feb 14, 2025MATERIAL CHANGE REPORT DATED FEBRUARY 14, 2025 Material Change Report dated
BioHarvest Sciences Inc. announced its voluntary delisting from the Canadian Securities Exchange (CSE), effective February 14, 2025. The company has received approval for this action, believing that the current trading volume on the CSE does not justify the costs associated with maintaining a dual listing. BioHarvest will continue to trade on the Nasdaq Global Market under the symbol 'BHST'. The management anticipates that this consolidation will improve liquidity and shareholder value.
Read more →-BHST
Feb 12, 2025BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar
BioHarvest Sciences Inc. will present at the WeBull Consumer Stocks Webinar on February 18, 2025. CEO Ilan Sobel will discuss the company's Botanical Synthesis technology and its impact on various industries. The presentation aims to highlight BioHarvest's growth and future opportunities in the nutraceutical and pharmaceutical sectors.
Read more →-BHST
Feb 12, 2025DATED FEBRUARY 12, 2025 News Release dated
BioHarvest Sciences Inc. has announced its participation in the WeBull Consumer Stocks Virtual Webinar scheduled for February 18, 2025. The company's CEO, Ilan Sobel, will present their patented Botanical Synthesis technology and its implications for multiple industries, including nutraceuticals and pharmaceuticals. Following the live event, a replay of the presentation will be available on the company's investor relations website. The information shared is expected to focus on the growth of BioHarvest's direct-to-consumer business and its upcoming opportunities in contract development and production services.
Read more →-BHST
Feb 11, 2025BioHarvest Sciences Announces Voluntary Delisting from CSE
BioHarvest Sciences Inc. has announced its voluntary delisting from the Canadian Securities Exchange (CSE), effective February 14, 2025. The company believes that the costs and efforts associated with maintaining a dual listing are no longer justified. This move aims to consolidate trading on the Nasdaq, potentially improving liquidity and shareholder value.
Read more →-BHST
Feb 10, 2025DATED FEBRUARY 10, 2025 Press Release dated
BioHarvest Sciences has announced its voluntary delisting from the Canadian Securities Exchange (CSE) after receiving approval. The company plans to streamline trading by focusing solely on its Nasdaq listing, which is anticipated to boost liquidity and shareholder value. The last trading day on the CSE is expected to be February 14, 2025. BioHarvest continues to operate in the field of Botanical Synthesis, enhancing its market presence through Nasdaq.
Read more →-BHST
Jan 23, 2025▼ -5.4%on this news
Item 1.Name and Address of Company
BioHarvest Sciences Inc. announced the appointment of Sharon Malka as an independent director. With over 25 years of experience in technology and capital markets, Malka's expertise is expected to contribute significantly to the company's growth. His operational background is well-aligned with BioHarvest's focus on developing cutting-edge therapeutic solutions through its Botanical Synthesis technology. The appointment aims to enhance the company's strategy as it progresses through a transformative phase.
Read more →-BHST
Jan 22, 2025BioHarvest Announces Appointment of Sharon Malka to Board of Directors
BioHarvest Sciences Inc. has appointed Sharon Malka as an independent director, effective immediately. Malka, a veteran in technology and finance, is expected to contribute significantly to the company's growth, particularly in advancing its Botanical Synthesis technology. His extensive experience includes leadership roles in various healthcare and technology firms, enhancing BioHarvest's strategic direction.
Read more →-BHST
Jan 8, 2025BioHarvest Issues Shareholder Letter and Provides Corporate Update
BioHarvest Sciences Inc. has issued a shareholder letter detailing significant growth in 2024, including the launch of its CDMO Services division and a successful partnership with Tate & Lyle. The company anticipates continued expansion in 2025, driven by new product lines and a robust pipeline. Additionally, BioHarvest's uplisting to Nasdaq is expected to enhance investor visibility and liquidity.
Read more →-BHST
Jan 8, 2025DATED JANUARY 8, 2025 News Release dated
BioHarvest Sciences Inc. announced a transformative year in 2024, highlighting growth in their core VINIA capsule business and the launch of a new CDMO Services division. The company forged a significant partnership with Tate & Lyle and is set to expand its product offerings to engage a wider consumer base. Additionally, a successful Nasdaq uplisting aims to boost visibility and attract U.S. investors. With strategic investments in infrastructure and technology, BioHarvest anticipates continued revenue growth and operational success in 2025.
Read more →-BHST
Dec 11, 2024Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients through Botanical Synthesis Technology
Tate & Lyle and BioHarvest have announced a partnership to develop next-generation plant-based ingredients using BioHarvest's Botanical Synthesis technology. This collaboration aims to create affordable and nutritious sweeteners that meet consumer demand for healthier options. The partnership leverages Tate & Lyle's expertise in ingredient solutions and BioHarvest's innovative production methods.
Read more →-BHST
Dec 11, 2024____________________________________________________________________________
Tate & Lyle and BioHarvest Sciences have formed a partnership to develop innovative plant-based ingredients using BioHarvest's Botanical Synthesis technology. The collaboration aims to create affordable and sustainable botanical sweeteners that align with consumer preferences for healthier food and beverage options. This partnership blends Tate & Lyle's extensive experience in ingredient solutions with BioHarvest's unique production capabilities. While the collaboration is promising, the commercialization and product suitability testing of the new sweeteners remain challenges.
Read more →-BHST
Nov 25, 2024BioHarvest Sciences Reports Third Quarter 2024 Financial Results
BioHarvest Sciences reported a 101% year-over-year revenue increase to over $6.5 million for Q3 2024, surpassing management's guidance. The company also expanded gross margins to 57% and launched new VINIA® SuperFood products. Despite these gains, net losses rose to $2.7 million, and operating expenses increased significantly. The company expects continued growth and margin improvements in upcoming quarters.
Read more →-BHST
Nov 25, 2024DATED NOVEMBER 25, 2024 News Release dated
BioHarvest Sciences reported a significant revenue increase of 101% year-over-year, reaching over $6.5 million for Q3 2024. The company's gross margins improved notably to 57% due to better manufacturing efficiencies. However, despite this growth, BioHarvest incurred a net loss of $2.7 million, reflecting increased operating expenses. The launch of new product lines and a substantial rise in VINIA subscribers indicate a robust business trajectory, despite challenges such as higher costs from geopolitical events.
Read more →-BHST
Nov 25, 2024BioHarvest Launches VINIA SuperFood Functional Tea Line
BioHarvest Sciences has announced the launch of its VINIA SuperFood functional tea line, featuring blends such as Black Tea, Green Tea, and Matcha Green Tea. This product aims to capture a share of the $3.3 billion North American functional tea market. The teas are infused with piceid resveratrol, mirroring the benefits of the existing VINIA supplements. The CEO emphasized the new line's potential to meet demand among younger consumers and its superiority in taste and efficacy compared to established brands.
Read more →-BHST
Nov 21, 2024BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024
BioHarvest Sciences Inc. will attend the Noble Capital Markets Emerging Growth Conference on December 3, 2024. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and present to attendees. The company has received positive feedback after its Nasdaq listing, indicating strong interest in its growth strategy.
Read more →-BHST
Nov 21, 2024DATED NOVEMBER 21, 2024 News Release dated
BioHarvest Sciences Inc. announced its participation in the Noble Capital Markets 20th Annual Emerging Growth Equity Conference scheduled for December 3, 2024, in Boca Raton, FL. CEO Ilan Sobel will engage with institutional investors and present the company's growth strategies. Following its recent Nasdaq listing, BioHarvest has received positive feedback, and the company aims to discuss advancements in commercializing plant-based molecules. A link to the presentation will be made available afterward on their investor relations website.
Read more →-BHST
Nov 18, 2024▲ +5%on this newsshared move
BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 p.m. Eastern Time
BioHarvest Sciences Inc. will announce its financial results for Q3 2024 on November 25, 2024. Following the release, management will host a conference call to discuss the results and provide a corporate update. Participants are encouraged to join the call at 4:30 p.m. Eastern Time.
Read more →-BHST
Nov 18, 2024▲ +5%on this newsshared move
VANCOUVER, CANADA, and REHOVOT, ISRAEL, November 15, 2024 - BioHarvest Sciences Inc.
BioHarvest Sciences Inc. has granted 5,400 Restricted Share Units and 111,998 stock options to employees and consultants, with a deemed issuance price of CAD $8.48 per share. The RSUs will vest after 12 months, while the stock options have various vesting terms extending up to 3 years. The company specializes in botanical synthesis aimed at creating therapeutic solutions and nutraceutical products. However, it has warned investors about the uncertainties surrounding future growth and profitability.
Read more →-BHST
Nov 18, 2024▲ +5%on this newsshared move
DATED NOVEMBER 18, 2024 News Release dated
BioHarvest Sciences Inc. has announced that it will release its third quarter 2024 financial results on November 25, 2024. The company will host an investor conference call to discuss these results and provide a corporate update. BioHarvest is known for its patented Botanical Synthesis technology, which allows for the production of plant-based molecules without the need to grow the actual plants. This call is an opportunity for investors to engage directly with the management team.
Read more →-BHST
Nov 12, 2024BioHarvest Sciences Begins Trading on the Nasdaq Global Market
BioHarvest Sciences Inc. has commenced trading on the Nasdaq Global Market under the ticker symbol 'BHST'. This listing is seen as a significant milestone that may enhance the company's public profile and liquidity. The company will also release its third quarter financial results on November 25, 2024, followed by an investor conference call.
Read more →-BHST
Nov 12, 2024DATED NOVEMBER 12, 2024 News Release dated
BioHarvest Sciences Inc. has announced that its shares will begin trading on the Nasdaq Global Market under the ticker symbol 'BHST'. This milestone is seen as a significant step in increasing the company's visibility and liquidity while broadening its potential shareholder base. The company is also set to release its third quarter financial results on November 25, 2024, and will host an investor conference call to discuss these results. BioHarvest uses its patented Botanical Synthesis technology for developing therapeutic solutions and nutraceutical products.
Read more →-BHST
Nov 7, 2024BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market
BioHarvest Sciences Inc. has announced its approval to list common shares on the Nasdaq Global Market under the ticker 'BHST', starting November 12, 2024. This move is anticipated to expand its shareholder base and improve liquidity. The company continues to trade on the OTCQB and CSE until the transition.
Read more →-BHST
Nov 7, 2024DATED NOVEMBER 7, 2024 News Release dated
BioHarvest Sciences Inc. announced its uplisting to the Nasdaq Global Market, with trading set to begin on November 12, 2024, under the ticker 'BHST'. This approval marks a significant milestone for the company and is expected to improve shareholder access and liquidity. The leadership expressed pride in the operational achievements that have led to this listing, aiming to expand their global shareholder base effectively. The company will continue to trade on the OTCQB until the transition is complete.
Read more →-BHST
Oct 28, 2024BioHarvest Sciences Appoints Bar Dichter as CFO
BioHarvest Sciences Inc. has appointed Bar Dichter as Chief Financial Officer, promoting her from her previous role as Vice President of Finance. This move is aimed at ensuring compliance with Nasdaq listing requirements and reflects the company's commitment to internal promotions and female leadership. Dichter has been with the company since 2018 and holds relevant academic qualifications.
Read more →-BHST
Oct 23, 2024BioHarvest Sciences Announces Record Preliminary Third Quarter 2024 Financial Results
BioHarvest Sciences Inc. announced record preliminary financial results for Q3 2024, with revenue expected to reach at least $6.5 million, marking a significant increase of 100% from the previous year. The company has also provided guidance for Q4 2024 revenues, predicting they could grow to at least $7.2 million. Moreover, BioHarvest is nearing completion of its Nasdaq listing application, intending to uplist by year-end, which could provide further market opportunities. However, the company anticipates net losses for the quarter, reflecting ongoing financial pressures alongside its growth plans.
Read more →-BHST
Oct 16, 2024BioHarvest Sciences to Participate in LD Micro Main Event XVII Conference on October 30, 2024
BioHarvest Sciences Inc. will participate in the LD Micro Main Event XVII Conference on October 30, 2024. CEO Ilan Sobel will host one-on-one meetings with institutional investors and a virtual presentation. The company anticipates growth in its business units and plans to introduce new products by Q4 2024, aiming for a Nasdaq listing by year-end.
Read more →-BHST
Oct 16, 2024DATED OCTOBER 16, 2024 News Release dated
BioHarvest Sciences Inc. announced its participation in the LD Micro Main Event XVII Conference on October 30, 2024, in Los Angeles. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and present virtually. He expressed optimism about the company's steady growth and plans to introduce new products in the fourth quarter of 2024, aiming for a Nasdaq listing by year-end. The event underscores BioHarvest's commitment to engaging with investors and showcasing its innovative Botanical Synthesis technology.
Read more →-BHST
Sep 20, 2024BioHarvest Sciences Reports Director’s Ongoing Key Role Following Resignation from Board
BioHarvest Sciences Inc. announced the resignation of David Ryan from its Board of Directors. Despite his departure from the board, Ryan will continue to play a crucial role as Vice President of Investor Relations. This move is part of the company's strategy to comply with Nasdaq's requirement for a majority of independent directors as it seeks to list its shares on the Nasdaq Stock Market.
Read more →-BHST
Sep 20, 2024Vancouver, British Columbia and Rehovot, Israel - September 20, 2024 - BioHarvest Sciences Inc.
BioHarvest Sciences Inc. announced the resignation of David Ryan as a director to comply with Nasdaq requirements for independent directors. Ryan will continue to serve as Vice President of Investor Relations. The Board expressed gratitude for his founding contributions to the company. This strategic move supports BioHarvest's plans to apply for a listing on the Nasdaq Stock Market, reflecting its growth intentions.
Read more →-BHST
Sep 20, 2024MATERIAL CHANGE REPORT DATED SEPTEMBER 20, 2024 Material Change Report dated
BioHarvest Sciences Inc. announced the resignation of David Ryan from its board of directors as part of a strategy to comply with Nasdaq's requirement for a majority of independent directors. Despite resigning from the board, Ryan will retain his position as Vice President of Investor Relations. This internal shift aims to improve the company's governance structure as it prepares for a potential listing on the Nasdaq Stock Market.
Read more →-BHST
Sep 12, 2024BioHarvest Sciences to Participate in iAccess Alpha Buyside Best Ideas Conference on September 24-25, 2024
BioHarvest Sciences Inc. has announced its participation in the iAccess Alpha Buyside Best Ideas Conference scheduled for September 24-25, 2024. CEO Ilan Sobel will host virtual meetings with institutional investors and a presentation during the event. The company aims to highlight its patented Botanical Synthesis technology and its applications in health and wellness.
Read more →-BHST
Sep 12, 2024DATED SEPTEMBER 12, 2024 Press Release dated
BioHarvest Sciences Inc. has been invited to present at the iAccess Alpha Buyside Best Ideas Conference, scheduled for September 24-25, 2024. CEO Ilan Sobel will host virtual one-on-one meetings with institutional investors and a public presentation. This event marks an opportunity for the company to showcase its patented Botanical Synthesis technology to potential investors. All interested parties can participate via an online webcast, with the aim of fostering investor relations and increasing visibility in the market.
Read more →-BHST
Sep 5, 2024MONTHLY PROGRESS REPORT DATED SEPTEMBER 5, 2024 Monthly Progress Report dated
BioHarvest Sciences Inc. (BHSC) released its monthly progress report reflecting strong performance in August 2024. The company reported a 119% revenue increase, driven by significant subscriber growth for its VINIA product line. Ongoing expansion plans include a new manufacturing facility and a variety of new product developments aimed at enhancing market presence. However, the company still faces net losses and operational challenges attributed to geopolitical events in Israel.
Read more →-BHST
Sep 4, 2024BioHarvest Sciences to Present at H.C. Wainwright 26th Annual Global Investment Conference
BioHarvest Sciences Inc. will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9-10, 2024. CEO Ilan Sobel will hold one-on-one meetings with institutional investors and deliver a presentation that will be available for public viewing. The event will take place at the Lotte New York Palace Hotel in New York City.
Read more →-BHST
Sep 4, 2024DATED SEPTEMBER 4, 2024 News Release Dated
BioHarvest Sciences Inc. will participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 9-10, 2024, in New York City. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and deliver a presentation that can be streamed live. This conference represents a significant opportunity for BioHarvest to showcase its patented Botanical Synthesis technology platform and engage directly with potential investors.
Read more →-BHST
Aug 29, 2024BioHarvest Sciences Reports Record Second Quarter 2024 Financial Results
BioHarvest Sciences reported a record revenue of $6.03 million for Q2 2024, marking a 119% increase year-over-year. The company anticipates third-quarter revenues of at least $6.5 million, supported by a 135% rise in VINIA® subscribers. Gross profit margins improved to 52%, reflecting ongoing operational enhancements. However, the company still reported a net loss of $0.7 million.
Read more →-BHST
Aug 29, 2024BioHarvest Sciences Surpasses USD $1.0 Million in Cumulative Direct Sales of Coffee with VINIA Inside
BioHarvest Sciences Inc. announced that its VINIA Superfood Coffee product line has surpassed USD $1.0 million in cumulative direct sales since its launch in December 2023. The product line, which incorporates the VINIA Red Grape Superfood into coffee pods, has received positive customer feedback, scoring 4.8 out of 5 in ratings. Additionally, taste tests showed consumer preference over leading competitors. CEO Ilan Sobel indicated that this success validates the company's strategy in the functional coffee market, with plans to expand by introducing new compatible pods.
Read more →-BHST
Aug 23, 2024BioHarvest Sciences to Host Second Quarter 2024 Corporate Update Call on August 29, 2024, at 2:30 p.m. Eastern Time
BioHarvest Sciences Inc. will host a corporate update call on August 29, 2024, led by CEO Ilan Sobel. The call will cover the company's Q2 2024 financial results, forecasts for Q3, and updates on their path to a Nasdaq listing. A live Q&A session will follow the presentation, allowing shareholders to engage directly.
Read more →-BHST
Jun 28, 2024BioHarvest Sciences Announces Closing of USD $4,329,982 in First Tranche of Private Placement and Conversion of Debt Notes
BioHarvest Sciences has successfully closed a private placement, raising approximately USD $4.33 million. The funds will be used to support its CDMO business unit and expand manufacturing capabilities. Additionally, the company has converted a significant portion of its convertible debt notes into common shares, indicating strong investor confidence.
Read more →-BHST
Jun 24, 2024BioHarvest Sciences to Present at Noble Capital Markets Virtual Equity Conference on June 27, 2024
BioHarvest Sciences Inc. will present at the Noble Capital Markets Virtual Equity Conference on June 27, 2024. CEO Ilan Sobel will host one-on-one meetings with institutional investors and a virtual presentation. The event aims to showcase the company's patented Botanical Synthesis technology and its applications in therapeutic solutions.
Read more →-BHST
Jun 21, 2024BioHarvest Sciences Announces a Private Placement of up to USD $5 Million and Conversion of Debt Notes
BioHarvest Sciences Inc. has announced a private placement of up to 697,350 units, aiming to raise up to $5 million. The funds will be used to advance its Contract Development and Manufacturing Organization (CDMO) business and expand manufacturing capabilities. Additionally, the company has converted a significant portion of its convertible debt notes into common shares.
Read more →-BHST
Jun 12, 2024BioHarvest Sciences to Present at Sidoti Small-Cap Virtual Investor Conference on June 13, 2024
BioHarvest Sciences Inc. has announced its participation in the Sidoti Small-Cap Investor Conference on June 13, 2024. CEO Ilan Sobel will host virtual meetings and a presentation during the event. Interested parties are encouraged to register for the webcast and participate in the discussions. The company specializes in Botanical Synthesis technology, aiming to develop innovative therapeutic solutions.
Read more →-BHST
Jun 6, 2024BioHarvest Sciences Announces Record $2 Million Monthly Sales
BioHarvest Sciences reported record sales of $1.98 million for May 2024, marking a 101% increase year-over-year, driven by strong subscription growth for its VINIA product line. The company plans to expand its product offerings, including new delivery systems and additional nutraceuticals. CEO Ilan Sobel expressed confidence in sustainable growth and aims for a Nasdaq listing by year-end.
Read more →-BHST
Jun 3, 2024BIOHARVEST SCIENCES INC. ANNOUNCES COMPLETION OF CONSOLIDATION
BioHarvest Sciences Inc. has successfully completed the consolidation of its common shares at a ratio of 35 to 1. Following this consolidation, 16,425,077 common shares are now issued and outstanding, with trading commencing on the Canadian Securities Exchange. The company continues to focus on its botanical synthesis technology for developing therapeutic solutions and nutraceutical products.
Read more →-BHST
May 30, 2024BioHarvest Sciences Reports First Quarter 2024 Financial Results
BioHarvest Sciences reported a strong financial performance for Q1 2024, with revenue increasing by 147% year-over-year to $5.34 million. The company also improved its gross margins to 56% and expects continued growth in Q2 2024. However, it reported a net loss of $6.6 million, highlighting ongoing financial challenges.
Read more →-BHST
May 30, 2024BIOHARVEST SCIENCES INC. ANNOUNCES SHAREHOLDER APPROVAL OF SHARE CONSOLIDATION
BioHarvest Sciences Inc. has announced the approval of a share consolidation by its shareholders, set to take effect on June 3, 2024. The consolidation will reduce the number of outstanding common shares from approximately 574 million to about 16 million. This move aims to enhance the company's stock value, although it is subject to regulatory approval.
Read more →-BHST
May 1, 2024BioHarvest Sciences to Host Corporate Update Call May 2 at 2:30 p.m. Eastern Time
BioHarvest Sciences Inc. will host a corporate update call on May 2, 2024, to discuss its recent achievements, including a significant revenue increase and a new corporate campus acquisition. CEO Ilan Sobel and Chairman Zaki Rakib will present the fourth quarter financial results and outline the company's growth strategy. The call will also feature a live Q&A session for shareholders.
Read more →-BHST
Apr 30, 2024BioHarvest Sciences Reports Fourth Quarter and Full Year 2023 Financial Results
BioHarvest Sciences reported a substantial revenue increase of 131% for FY 2023, reaching $12.7 million. The company anticipates Q1 2024 revenues between $5.2 million and $5.3 million, with further growth expected from new product launches. Management is pursuing a Nasdaq listing to improve market visibility and has called a special meeting to approve share consolidation. Despite the positive growth, the company reported a net loss of $12.6 million for the year.
Read more →-BHST
Apr 16, 2024BioHarvest Sciences Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity
BioHarvest Sciences has announced the opening of a new 80,000 square foot facility in Yavne, Israel, which includes 12 GMP clean rooms and space for a 50-ton manufacturing facility. This development aims to support the growth of their CDMO business unit and optimize production technologies. The facility is expected to enhance operational efficiency and accommodate future expansions.
Read more →-BHST
Apr 4, 2024BioHarvest Sciences Announces Conversion of Debt Notes
BioHarvest Sciences Inc. has announced the early conversion of CAD $16,742,435.22 in convertible debt notes into 73,268,708 common shares. This conversion is part of financing rounds completed from October 2022 to December 2023. The company also issued 39,775,554 Early Exercise warrants, enhancing its financial flexibility.
Read more →-BHST
Mar 21, 2024BioHarvest Sciences Appoints Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables
BioHarvest Sciences has appointed Anna Tenstam as VP of Business Development for its new CDMO business unit. With over 30 years of experience in life sciences, Tenstam aims to drive growth in cosmeceuticals and injectables. Her extensive industry connections are expected to enhance BioHarvest's ability to secure development and manufacturing contracts.
Read more →-BHST
Mar 15, 2024BioHarvest Sciences to Participate in Benzinga Virtual Healthcare Summit 2024 on March 20, 2024
BioHarvest Sciences Inc. has been invited to participate in the Benzinga Virtual Healthcare Summit 2024, scheduled for March 20, 2024. CEO Ilan Sobel will host a fireside chat to discuss the company's recent milestones and provide updates. The summit will cover various topics in healthcare and biotech, attracting industry leaders and analysts.
Read more →-BHST
Mar 13, 2024BioHarvest Sciences Announces New Strategic Hires for CDMO Services Business Unit
BioHarvest Sciences has appointed Matt Zrebiec and Professor Itay Mayrose to key leadership roles in its newly launched CDMO Services Business Unit. Zrebiec will focus on business development while Mayrose will lead AI-driven initiatives. The company aims to leverage their expertise to accelerate growth and capitalize on emerging opportunities in the pharmaceutical, cosmetics, and nutrition sectors.
Read more →-BHST
Mar 7, 2024BioHarvest Sciences to Participate in iAccess Alpha Buyside Best Ideas Conference on March 12-13, 2024
BioHarvest Sciences Inc. has announced its participation in the iAccess Alpha Buyside Best Ideas Conference on March 12-13, 2024. CEO Ilan Sobel will host virtual one-on-one meetings with institutional investors and present at the conference. The event aims to highlight the company's patented Botanical Synthesis technology and its applications in therapeutic solutions.
Read more →-BHST
Mar 7, 2024BioHarvest Sciences to Host Corporate Update Discussing Launch of CDMO Business Unit on March 13 at 2:30 p.m. Eastern Time
BioHarvest Sciences Inc. announced a corporate update webinar scheduled for March 13, 2024, to discuss the launch of its new Contract Development and Manufacturing Organization (CDMO) business unit. This initiative aims to provide pharmaceutical and nutraceutical companies with access to BioHarvest's patented Botanical Synthesis technology. The company anticipates that this new unit will facilitate the development of novel therapeutic molecules while expanding its intellectual property library.
Read more →-BHST
Feb 26, 2024BioHarvest Sciences Signs First Contracts with Two Industrial Customers to Develop Complex Molecules via its Newly Launched Botanical Synthesis CDMO Business Unit.
BioHarvest Sciences has launched a new Contract Development and Manufacturing Organization (CDMO) business unit, signing contracts with two industrial customers to develop complex molecules. This initiative leverages their proprietary Botanical Synthesis technology, which offers advantages in cost and speed of development. The contracts, however, come with confidentiality clauses and uncertainties regarding future progress.
Read more →-BHST
Feb 15, 2024BioHarvest Sciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
BioHarvest Sciences has engaged MZ Group to enhance its investor relations and financial communications. This collaboration aims to promote the company's Botanical Synthesis technology, which is expected to drive significant revenue growth. The company anticipates a 125% increase in revenue for 2023, with a focus on achieving profitability in 2024. However, future results are subject to market uncertainties.
Read more →-BHST
Feb 12, 2024BioHarvest Sciences to Present at the 2024 BIO CEO & Investor Conference
BioHarvest Sciences Inc. will participate in the 2024 BIO CEO & Investor Conference in New York City on February 26-27, 2024. CEO Ilan Sobel and other executives will host meetings with investors and present the company's innovative botanical synthesis technology. The conference is a key platform for showcasing advancements in biotechnology and networking with industry leaders.
Read more →-BHST
Jan 8, 2024BioHarvest Issues 2023 Year End Shareholder Letter and Provides Corporate Update
BioHarvest Sciences Inc. reported a strong year in 2023, with significant revenue growth driven by its flagship product, VINIA®. The company plans to expand its product offerings and enter new markets, including Canada and Europe. CEO Ilan Sobel expressed confidence in achieving profitability in 2024, supported by operational efficiencies and a solid financial position.
Read more →-BHST
Dec 27, 2023BIOHARVEST SCIENCES INC. CLOSES FINAL TRANCHE OF OVERSUBSCRIBED $13.5M PRIVATE PLACEMENT
BioHarvest Sciences Inc. has successfully closed the final tranche of its oversubscribed $13.5 million private placement, raising a total of CA$ 13,622,873.26. The financing will support the company's strategic plans to achieve profitability in 2024, leveraging its patented Botanical Synthesis technology. The convertible notes issued will bear interest at 12% per annum and have a term of 24 months.
Read more →-BHST
Dec 13, 2023BIOHARVEST SCIENCES ANNOUNCES MAJOR PRODUCT LAUNCH OF VINIA-BASED FUNCTIONAL COFFEES
BioHarvest Sciences has announced the launch of VINIA Superfood Coffee, aiming to disrupt the $6 billion US coffee pod market. This product is the first of three major launches under the 'VINIA Inside' strategy, which combines health benefits with convenience. The company expects significant revenue growth, with guidance for Q4 2023 set between $4.2 million and $4.5 million.
Read more →-BHST
Dec 1, 2023BIOHARVEST SCIENCES TO HOST VIRTUAL SHAREHOLDER UPDATE DECEMBER 13, 2023, 2:30pm ET
BioHarvest Sciences Inc. will host a virtual Q3 Performance Update on December 13, 2023, led by CEO Ilan Sobel. The session will cover the company's financial performance, including a 113% revenue increase year-over-year and plans for the launch of VINIA functional coffee. A live Q&A session will follow the presentation.
Read more →-BHST
Nov 29, 2023BIOHARVEST SCIENCES REPORTS Q3 2023 REVENUE DEMONSTRATING CONTINUED GROWTH MOMENTUM
BioHarvest Sciences reported a strong Q3 2023, with revenues of USD 3.24M, reflecting a 113% increase year-over-year. The gross profit margin improved to 45%, and active subscribers rose by 213%. Despite a projected revenue shortfall for 2023, the company remains optimistic about future growth and product launches. A shareholder event is scheduled for December 13 to discuss results and initiatives.
Read more →-BHST
Oct 30, 2023BIOHARVEST SCIENCES INC. ANNOUNCES $11.78M RAISED IN FIRST TRANCHE OF $13.5M PRIVATE PLACEMENT
BioHarvest Sciences Inc. has successfully closed the first tranche of a private placement, raising CA$11.78 million as part of a larger CA$13.5 million financing effort. CEO Ilan Sobel emphasized the financing as a validation of the company's growth strategy, particularly in leveraging its Botanical Synthesis Platform Technology. The funds will support increased production capacity and expansion into various markets.
Read more →-BHST
Oct 10, 2023HEALTH CANADA GRANTS BIOHARVEST SCIENCES LICENSE FOR VINIA SALES IN CANADA
BioHarvest Sciences Inc. has received a product license from Health Canada for its flagship nutraceutical product, VINIA®, allowing sales in Canada. This marks a significant step in the company's global expansion strategy, with plans to begin marketing in early 2024. The product is clinically proven to support cardiovascular health and will be marketed through various channels, including e-commerce and retail.
Read more →-BHST
Sep 6, 2023BIOHARVEST ANNOUNCES AUGUST 2023 U.S. VINIA SALES EXCEEDED USD $1MILLION
BioHarvest Sciences Inc. announced that its flagship product, VINIA®, achieved over USD 1 million in sales for August 2023, marking a significant milestone. The company attributes this success to its Botanical Synthesis technology and effective direct-to-consumer sales strategy. CEO Ilan Sobel expressed confidence in future revenue growth as they prepare to launch additional products. However, the company also reported a net loss in Q2 and faces uncertainties regarding future profitability.
Read more →-BHST
Aug 30, 2023BIOHARVEST SCIENCES REPORTS Q2 2023 RESULTS DEMONSTRATING CONTINUED GROWTH MOMENTUM
BioHarvest Sciences reported significant growth in Q2 2023, with VINIA revenues reaching USD 2.75M, a 228% increase from the previous year. The company also saw a 620% rise in active subscribers. Despite production capacity constraints, BioHarvest aims for cash flow break-even by late 2023 and profitability in early 2024. CEO Ilan Sobel highlighted ongoing efforts to meet demand and introduce new products.
Read more →-BHST
Aug 24, 2023BIOHARVEST SCIENCES TO HOST VIRTUAL SHAREHOLDER PRESENTATION SEPTEMBER 6, 2023, 2:30 PM ET
BioHarvest Sciences Inc. will host a virtual Q2 Performance Update Presentation on September 6, 2023, led by CEO Ilan Sobel. The session will cover the company's financial results and marketing strategies for its VINIA product. Investors and media are invited to participate and submit questions during the live Q&A.
Read more →-BHST
Jul 18, 2023BIOHARVEST SCIENCES INC. ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF CONVERTIBLE NOTES
BioHarvest Sciences Inc. has successfully closed a non-brokered private placement of convertible notes totaling CA$4,642,075.50. CEO Ilan Sobel highlighted the company's ability to attract funding despite challenging market conditions, emphasizing strong investor support. The notes will be subject to a hold period under Canadian securities laws. BioHarvest focuses on developing innovative therapeutic solutions using its patented bio-cell growth technology.
Read more →Competitive Position
How BHST ranks across every disease it competes inCompetitive Position is a premium feature
See how BHST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial